iPS Cells & Regenerative Medicine– category –
-
DelveInsight Reports Robust Parkinson’s Disease Pipeline: Over 240 Therapies in Clinical and Preclinical Development
DelveInsight USA Overview DelveInsight's "Parkinson's Disease Pipeline Analysis, 2026" reveals a highly active R&D landscape with over 240 therapies in clinical and preclinical stages. This extensive pipeline spans diverse modalities... -
Japan Reinforces LMO Safety Regulations for Advanced Biotech Research and Regenerative Medicine
厚生労働省 Japan Overview Japan's Ministry of Health, Labour and Welfare (MHLW) has reissued critical guidelines on the contained use (Type 2) of living modified organisms (LMOs) under the Cartagena Act. This re-notification emphasizes s... -
DelveInsight: 180+ Companies Propel CAR-T Innovation, Forging a New Era in Cell Therapy
DelveInsight USA Overview A new DelveInsight report reveals the significant expansion of the CAR-T cell therapy pipeline, with over 180 companies driving innovation. Projecting substantial market growth by 2036, the report highlights key... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ... -
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a... -
BlueRock Therapeutics Initiates Patient Enrollment for Parkinson’s Disease iPSC-Derived Cell Therapy exPDite-2 Phase 3 Trial; Long-Term Follow-Up Data Imminent
Neurology Live USA Overview BlueRock Therapeutics has initiated patient enrollment for its Phase 3 exPDite-2 clinical trial, transplanting iPSC-derived dopaminergic neurons in Parkinson's disease patients. The trial will involve approxim... -
CRISPR Therapeutics Demonstrates Future Potential with Casgevy Approval, Leading Gene-Editing Market Through Pipeline Diversification
Intellectia.AI USA Overview CRISPR Therapeutics has established market leadership with the FDA approval of Casgevy, its gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. In 2025, 64 patients receive... -
Fujifilm Reshuffles Life Sciences Leadership and Opens New Facility to Quadruple iPSC Manufacturing Capacity
FUJIFILM Holdings America Corporation Press Release USA Overview FUJIFILM Holdings America Corporation announced a reshuffle in the leadership of its life sciences group, with Delara Motlagh appointed as President and COO of FUJIFILM Cel... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi...
